To determine the cut-off points effective as poor prognostic factors of DM-IP, we performed ROC curve analysis on the serum chemokine levels (CCL2, CXCL10, and CXCL11) at 2 weeks after treatment initiation. The gene discussed is CXCL11; the disease is dermatomyositis.